epilepsy, partial seizures
Neurology · 2005–2012
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lacosamide Add-on therapy for partial-onset seizures with or without secondary generalisation in patients with drug-resistant epilepsy aged 16 years or older. | Nov 2012 | Recommended with restriction | no section in document |
| pregabalin Adjunctive therapy for partial epileptic seizures not satisfactorily controlled by other anti-epileptic drugs in patients 18 years of age or older. | Jul 2005 | Recommended with restriction | no section in document |
What the PBS pays
$69M in government benefit over 2024–25, across 3,476,376 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pregabalin | $54.3M |
| lacosamide | $15M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.